Sugi Predict

Sugi Predict / Compounds / SCHEMBL1922037

SCHEMBL1922037

SCHEMBL1922037

CCOC(=O)c1cc(C)n(-c2c(C)nn3c(-c4ccc(Cl)cc4Cl)c(C)oc23)n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 2/20 0.45
▸ DPP8 Q6V1X1 1/20 0.45
▸ DPP9 Q86TI2 1/20 0.45
▸ TSHR P16473 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ GABRA2 P47869 8/20 0.40
▸ GABRB2 P47870 8/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922758 0.85 MAPT (0.42) DPP4DPP8DPP9TSHRMAPT
SCHEMBL1922467 0.81 DPP4 (0.42) DPP4DPP8DPP9TSHRNPC1
SCHEMBL1922397 0.81 CRHR1 (0.37) DPP4DPP8MAPTPOLB
SCHEMBL2258055 0.77 PTGS1 (0.39) DPP4DPP8TSHRMAPTHSD17B10
SCHEMBL1922346 0.77 MAPT (0.46) DPP4DPP8DPP9TSHRMAPT
SCHEMBL29419139 0.77 GABRA2 (0.59) MAPTSMN1; SMN2GABRA2GABRB2LMNA
SCHEMBL340947 0.77 GABRA2 (0.59) MAPTSMN1; SMN2GABRA2GABRB2LMNA
SCHEMBL1923091 0.76 DPP4 (0.39) DPP4DPP8MAPTNPC1HSD17B10
SCHEMBL1922662 0.75 DPP4 (0.41) DPP4DPP8DPP9NPC1
SCHEMBL1922525 0.74 DPP4 (0.44) DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011529943-A — — 2011-12-15 — — JP claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US claimed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP claimed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO claimed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 DPP4 958/4885DPP8 593/4885DPP9 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.